Rocket


Overview
Financials
News + Filings
Key Docs
Ownership
Insiders


All
All (ex-4s)
10-K
10-Q
8-K
3,4,5
Proxy
Prospectus
Other
Tags
Quarterly results
HCW Biologics Inc. Create: Alert

All | News | Filings
Date FiledTypeDescription
08/24/2023 8-K Other Events  Interactive Data
08/11/2023 10-Q Quarterly Report for the period ended June 30, 2023
08/11/2023 8-K Quarterly results
Docs: "HCW Biologics Reports Second Quarter 2023 Financial Results And Recent Business Highlights Miramar, FL – August 11, 2023 – HCW Biologics Inc. , a clinical-stage biopharmaceutical company focused on discovering and developing novel immunotherapies to lengthen healthspan by disrupting the link between inflammation and age-related diseases, today reported financial results and recent business highlights for its second quarter ended June 30, 2023. “During the period ended June 30, 2023, we have made significant progress in crystalizing our understanding of the anti-cancer mechanism of action of HCW9218, especially in relation to how it complements immune checkpoint inhibitors . HCW9218 has a unique mechanism that we believe allows it to turn a ‘cold’ tumor into a ‘hot’ tum..."
08/10/2023 10-Q/A Quarterly Report for the period ended March 31, 2023 [amend]
05/09/2023 10-Q Quarterly Report for the period ended March 31, 2023
05/09/2023 8-K Quarterly results
Docs: "HCW Biologics Reports First Quarter 2023 Financial Results And Recent Business Highlights Miramar, FL – May 9, 2023 – HCW Biologics Inc. , a clinical-stage biopharmaceutical company focused on discovering and developing novel immunotherapies to lengthen healthspan by disrupting the link between inflammation and age-related diseases, today reported financial results and recent business highlights for its first quarter ended March 31, 2023. “We measure our progress over the past year by the achievement of significant milestones: Initiating multiple clinical trials. Realizing the dream of establishing our own manufacturing facility. Publishing ground-breaking scientific papers,” stated Dr. Hing C. Wong, Founder and CEO of HCW Biologics. Dr. Wong continued, “Our primary pr..."
04/27/2023 ARS Form ARS - Annual Report to Security Holders:
04/27/2023 DEFA14A Form DEFA14A - Additional definitive proxy soliciting materials and Rule 14(a)(12) material:
04/27/2023 DEF 14A Form DEF 14A - Other definitive proxy statements:
04/27/2023 8-K Quarterly results
03/28/2023 10-K Annual Report for the period ended December 31, 2022
03/28/2023 8-K Quarterly results
12/07/2022 8-K Other Events  Interactive Data
11/07/2022 10-Q Quarterly Report for the period ended September 30, 2022
11/07/2022 8-K Quarterly results
Docs: "HCW Biologics Reports Third Quarter 2022 Financial Results And Recent Business Highlights Miramar, FL – November 7, 2022 – -- HCW Biologics Inc. , a clinical-stage biopharmaceutical company focused on discovering and developing novel immunotherapies to lengthen healthspan by disrupting the link between chronic, low-grade inflammation and age-related diseases, today reported financial results and recent business highlights for its third quarter ended September 30, 2022. Hing C. Wong, Ph.D., Founder and CEO of HCW Biologics, stated, “We are pleased to report that during the third quarter we opened three clinical sites for our second clinical trial to evaluate HCW9218 in patients with advanced pancreatic cancer. HonorHealth Research Institute was the first clinical site to dose a patie..."
08/19/2022 S-3 Form S-3 - Registration statement under Securities Act of 1933:
08/03/2022 8-K Regulation FD Disclosure, Financial Statements and Exhibits  Interactive Data
Docs: "U.S. Patent Issued to HCW Biologics for Foundational Platform Technology Issued Claims for Single-Chain Chimeric Polypeptide and Composition Claims for Lead Product Candidate, HCW9302 Miramar, FL – August 3, 2022 – HCW Biologics Inc. NASDAQ: HCWB), a clinical-stage biopharmaceutical company focused on discovering and developing novel immunotherapies to lengthen healthspan by disrupting the link between chronic, low-grade inflammation and age-related diseases, was granted U.S. Patent 11,401,324 which contains claims for immunotherapeutic compounds comprised of a single-chain chimeric polypeptide with two target-binding domains on a scaffold made of an extracellular domain of human tissue factor. This patent provides intellectual property protection for the lead drug candidate, HCW9302, a si..."
06/17/2022 8-K Quarterly results
05/19/2022 8-K Quarterly results
05/13/2022 10-Q Quarterly Report for the period ended March 31, 2022
05/13/2022 8-K Quarterly results
04/25/2022 DEF 14A Form DEF 14A - Other definitive proxy statements:
03/29/2022 10-K Annual Report for the period ended December 31, 2021
03/28/2022 8-K Quarterly results
Docs: "HCW Biologics Reports Fourth Quarter and Full Year 2021 Financial Results and Business Highlights for 2021 $56 Million IPO Completed in July 2021 Expected to Fund Operating Expenses through 2023 FDA Clearance for Initial Clinical Trials in Two Difficult-to-Treat Cancer Indications Publication of Three Pivotal Scientific Papers in Peer-Reviewed Journals Miramar, FL – March 28, 2021 – HCW Biologics Inc. , a biopharmaceutical company focused on discovering and developing novel immunotherapies to lengthen health span by disrupting the link between chronic, low-grade inflammation and age-related diseases, today reported recent business highlights and financial results for its fourth quarter and full year ended December 31, 2021. Dr. Hing C. Wong, the Founder and CEO of HCW Biologics, stated, &#..."
01/24/2022 8-K Regulation FD Disclosure, Financial Statements and Exhibits  Interactive Data
Docs: "Tiberend Strategic Advisors, Inc."
11/12/2021 10-Q Quarterly Report for the period ended September 30, 2021
11/12/2021 8-K Quarterly results
Docs: "HCW Biologics Reports Third Quarter Financial Results and Recent Business Highlights Miramar, FL - November 12, 2021 - — HCW Biologics Inc. , an innovative biopharmaceutical company focused on discovering and developing novel immunotherapies to lengthen health span by disrupting the link between chronic, low-grade inflammation and age-related diseases, today reported recent business highlights and financial results for its third quarter ended September 30, 2021. “The third quarter of 2021 and recent weeks were an important period for HCW Biologics and our strategy to build a pipeline of first-in-class immunotherapeutic treatments for age-related diseases,” stated Hing C. Wong, Ph.D., founder and CEO of HCW Biologics Inc. “The third quarter provided bookends to what has been a busy time for..."
10/28/2021 8-K Regulation FD Disclosure, Financial Statements and Exhibits  Interactive Data
Docs: "UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549",
"Tiberend Strategic Advisors, Inc."
10/27/2021 8-K Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements...
08/13/2021 10-Q Quarterly Report for the period ended June 30, 2021
08/13/2021 8-K Quarterly results
Docs: "HCW Biologics Reports Second Quarter Financial Results and Recent Business Highlights Miramar, FL - August 13, 2021 - HCW Biologics Inc. , an innovative biopharmaceutical company focused on discovering and developing novel immunotherapies to lengthen health span by disrupting the link between chronic, low-grade inflammation and age-related diseases, today reported financial results and recent business highlights for its second quarter ended June 30, 2021. “HCW Biologics delivered on a milestone as we achieved our goal of closing our initial public offering on July 22 to raise capital to advance the clinical development of our lead molecules,” stated Hing C. Wong, Ph.D., founder and CEO of HCW Biologics Inc. “We started HCW Biologics three years ago with an idea to develop immunotherapeutic..."
08/02/2021 SC 13D Wong Hing C reports a 42.7% stake in HCW BIOLOGICS INC.
07/26/2021 8-K Quarterly results
07/21/2021 S-8 Form S-8 - Securities to be offered to employees in employee benefit plans:
  Next >>

Rocket Data Systems, Inc. © 2019 | Contact Us | Data Disclaimer | Terms of Use | Privacy